therapeutic options following failure to jak inhibitors
Published 2 years ago • 543 plays • Length 3:19Download video MP4
Download video MP3
Similar videos
-
2:22
the need for novel agents to treat patients with mcl who have relapsed after targeted therapy
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf
-
3:07
clinical guidance for the use of jak inhibitors when treating patients with mf
-
2:04
novel therapies for myelofibrosis patients who have failed jak inhibitors
-
3:13
therapies for patients who progress on jak inhibitors: imetelstat, navtemadlin, selinexor & tp-3654
-
0:53
investigating the place of jak inhibitors in the treatment of myelofibrosis
-
1:34
targeting the pi3k pathway in patients who fail jak inhibitor therapy
-
12:09
jak inhibitors in mf: tailoring treatment strategies
-
3:51
novel agents in mzl: btkis, pi3k inhibitors, and immunotherapeutics
-
7:03
jak2 v617f vaf as a diagnostic and prognostic marker for polycythemia vera and thrombosis risk
-
1:59
assessing if a patient with dlbcl is responding to treatment using pet-ct and novel assays
-
2:23
factors to consider when selecting jak inhibitors for patients with mf
-
2:47
analysis of jak inhibitors and risk of secondary b-cell lymphomas in mpn patients
-
2:52
jak inhibitor combination therapy for the treatment of myelofibrosis
-
1:15
drugs under investigation for patients with mf who have failed treatment with jak inhibitors
-
3:52
optimizing the selection between available jak inhibitors in myelofibrosis
-
1:39
treating patients with myelofibrosis who are intolerant to or develop resistance to jak inhibitors
-
1:47
moving beyond jak inhibitors: novel targets and pathways being explored for the treatment of mpns
-
4:16
jak inhibitor selection & sequencing in myelofibrosis
-
1:23
targeted therapies beyond jak inhibitors
-
3:21
looking beyond jak inhibitors: novel targeted therapies and strategies for mpn treatment
-
3:48
jak inhibition for the early treatment of myelofibrosis